Participating Personnel

    Hagen BriesenProfessor Dr. Hagen v. Briesen (male), First Time FET Participant, is Director of Division “Medical Biotechnology” at the Fraunhofer Institute for Biomedical Engineering (IBMT in Sulzbach/Saar, Germany) and Professor for Experimental Hematology at the University of Saarland. He studied biochemistry at the University of Frankfurt/Main (PhD in 1990). Since 2001 he had been assistant professor for Experimental Hematology at the University of Regensburg. He is Principle Investigator of the Global HIV Vaccine Research Cryorepository (GHRC, Collaboration for AIDS Vaccine Discovery (CAVD)) (Bill & Melinda Gates Foundation), and is involved in joint research projects in cell programming by nanoscaled devices and nanoparticulate drug delivery systems to overcome biological barriers such as the blood-brain barrier (EU, BMBF and Federal Armed Forces). He is external expert in an interdisciplinary EU-funded support action on HIV-MTB co-infection “EUCO-Net”. He is co-founder of a start-up company (Analysis GmbH) for virus validation and safety studies where he introduced Good Laboratory Practice (GLP) as test facility manager. Hagen von Briesen was Principal Investigator of the Centralized Facility for the Isolation and Characterization of HIV within the WHO-Network, Global Program on AIDS, organized by the Joint United Nations Program on HIV/AIDS (UNAIDS). HIV-1 strains from different parts of the world were systematically isolated in his laboratory and characterized by the WHO Network. Concurrently, he was member of the trial management committee of the Mother-to-Child HIV-1 Transmission Study (UNAIDS-sponsored PETRA study) functioning as Head of Centralized Repository Centre and test laboratory. As of late, he is director of the Environmental Specimen Bank (UPB-human) of the Federal German Government.

    Sylvia WagnerDr. Sylvia Wagner (female), First Time FET Participant, is Head of the Department “Bioprocessing & Bioanalytics” at Fraunhofer IBMT. She studied chemistry at the University Karlsruhe. She gained her PhD thesis in the group of Prof. Dr. H. v. Briesen at IBMT. From 2008-2016 she was group manager at IBMT and became head of department in 2015. Her main research topics are focused on nanobiotechnology and development of preclinical in vitro/ex vivo models in the field of nanotoxicology as well as nanomedicine. Nanoparticulate formulations for the specific drug targeting as well as for crossing of biological barriers were preclinically tested in different in vitro and ex vivo cell culture models. Her department has established e.g., several blood-brain barrier cell culture models, a gastrointestinal barrier model, a lung model and a dermal barrier model for permeation studies. Her department was and still is involved in several joint research projects in the field of drug delivery systems based on nanotechnologies which were and are funded by EU and BMBF (“NanoDrug”; “NanoCancer”; “NanoBrain”; “BioTrap for CCC”) as well as projects supported by the German Federal Armed Forces and the private industry. One of her actual projects called “GITCare” is focused on the oral delivery of nanoparticulate packaged drugs for tumour therapy. Furthermore, several projects based on nanoparticle risk assessment are coming more and more into focus, e.g., the BMBF funded projects “MINAC” and “NanoUmwelt” and the EU funded project “HISENTS”.

    Julia NeubauerDr. Julia Neubauer (female), First Time FET Participant, is Head of the Department “Cryo & Stem Cell Technology” at Fraunhofer IBMT. She studied Biology at the Julius-Maximilians-University of Würzburg and received her PhD in 2012 after joining Fraunhofer IBMT as project manager five years before. During these years she spent also some time abroad, visiting the University of Vienna/Austria and the University of Coquimbo/Chile for research stays and the evaluation of process techniques. Since 2012 she was leading the work group “Cell Culture Automatization” at Fraunhofer IBMT in St. Ingbert. Since 2015 Julia Neubauer was appointed Head of Department. Her main research topics are focused on establishing new automation procedures for the optimization of stem cell workflows using suspension bioreactors and robotic/microfluidic platforms. For this, cell culture protocols are adapted and improved, for example by using biopolymers as microcarrier system. Besides, innovative cryopreservation procedures are developed for the efficient storage of high-quality cell material.

    Marc FournelleDr. Marc Fournelle (male), First Time FET Participant, is Head of Business Area “Biomedical Ultrasound“ at Fraunhofer IBMT. He studied Physics at the University of Saarland and Barcelona and received his PhD in 2009 after joining the Ultrasound Department of Fraunhofer IBMT in 2005. Since 2011 he was head of the work group “Biomedical Ultrasound Research”, became Head of Department “Medical Ultrasound” in 2015 and is now Head of Business Area “Biomedical Ultrasound” since 2016. His main areas of research are ultrasound and optoacoutic imaging, signal processing and reconstruction algorithms, as well as therapeutic ultrasound.

     Ina MeiserDr. Ina Meiser (female), First Time FET Participant leads the work group “Cryobiotechnology” that focusses in lab automation, especially regarding hiPSCs research and novel cryopreservation approaches.


    © 2019 Gladiator Project. All Rights Reserved.